Sanofi Consumer Healthcare India Ltd
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare BSE 1000
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
| Free Cash Flow |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit |
Ratios
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Insights
In beta| Dec 2023 | Dec 2024 | Dec 2025 | |
|---|---|---|---|
| Advertisement & Sales Promotion as % of Revenue % ・Standalone data |
|
||
| Brand Market Share (IQVIA MAT) % ・Standalone data |
|||
| Field Force (Medical Representatives) count ・Standalone data |
|||
| Number of Dealers/Distributors count ・Standalone data |
|||
| Cities Served count ・Standalone data |
|||
| HCP Digital Engagement Reach count ・Standalone data |
|||
Extracted by Screener AI
Documents
Announcements
-
Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results For The Quarter And Nine Months Ended 30Th September 2026.
- Board meeting on 28 October 2026 to approve Q2 and nine-month FY2026 unaudited results; trading window closed until 30 October.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
- Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th September 2026 is enclosed.
- Closure of Trading Window
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Copy of Newspaper Publication of Unaudited Financial Results for the quarter and half year ended 30th June 2026 is enclosed.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
- Board approved Q2 FY26 results: revenue ₹2,357 million, net profit ₹919 million; H1 revenue ₹4,649 million.
Annual reports
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2024
from bse
Concalls
-
Mar 2026Transcript PPT
Business Overview:[1][2]
SCHIL was formed following its demerger
from Sanofi India Limited, to establish a standalone Consumer Healthcare (CHC) business. It operates in the Consumer Healthcare (CHC) sector, providing self
-care solutions across various health
categories including allergy relief,
pain management, and wellness.
The Goa unit and prescription/
general-medicines business
remained with Sanofi India;
SCHIL is now a focused fast
-moving consumer-healthcare
company.